Tagged With car-t

This week marked a major milestone in medicine: On Wednesday, a US Food and Drug Administration panel unanimously recommended the approval of the first CAR-T therapy, a pioneering new cancer drug from Novartis that genetically engineers a patient's own white blood cells to recognise and attack the cancer cells invading their body.

Following the deaths of five patients, Juno Therapeutics has decided to pull the plug on an experimental cancer treatment that boosts the power of a patient's immune cells. The news comes just days after the company's rival, Kite Pharma, announced its success with a similar method, showing there's still hope for this potentially revolutionary gene therapy.

Clinical trials of a promising new therapy, in which white blood cells are reprogrammed to attack cancer cells, has resulted in the deaths of three patients. In response, the US Food and Drug Administration has ordered a temporary halt to the trial.